Systematic Review of Future Direction of Broadly Neutralizing Antibodies against HIV

Abstract

A novel class of potential therapeutic agents is provided by the recent invention of the broadly neutralizing highly potent HIV-specific monoclonal antibodies (bnAbs). It has broadly been recognized that neutralising antibodies can hit the HIV envelope (Env) and efficiently subdue viral retort inex vivo (vitro) but bnAbs aren’t effective enough for practical use. The bnAbs are being sturdily followed and developed due to the imperative features, including the engaging the host immune response, excellent safety, and longer half-life. It has been reported the functions in a variety of studies, for instance clearing infected cells, inhibiting cell-to-cell transmittance, and neutralizing free virus of HIV-1. Furthermore, the upward contourofbnAbs renders new-fangled vision for cogent vaccine design and anticipating immunogen examination.To result in suboptimal or sporadic treatment, all these factors work together that hikes the menace of treatment failure and viral resistance. A highly priority is still remained to quest for novel preventive and therapeutic interventions. An attractive new therapeutic modality against HIV/AIDS is known Antibodies. Antibodies not only can directly target explicit viral epitopes but also have the potential to tackle host immune receptions.